This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Wavefront-guided LASIK for Correction of Myopia

This study has been withdrawn prior to enrollment.
(Institution changed surgical method to small-incision lenticule extraction. Study never started.)
Sponsor:
Information provided by (Responsible Party):
Anders Ivarsen, Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT01682434
First received: September 4, 2012
Last updated: April 30, 2014
Last verified: April 2014
  Purpose

Laser in situ keratomileusis is a successful procedure for the treatment of low to moderate myopia.

Advances over the last decade have allowed LASIK to also correct higher order wavefront aberrations. In low myopia, there seem to be a minor effect of such wavefront-guided treatment. However, it remains to be established whether there is a beneficial effect in higher degrees of myopia.

The study aims to determine whether myopic subjects (-6 to -10 diopters) with higher-than-average preoperative higher-order aberrations have benefit of wavefront-guided treatment. Subjects are randomized to wavefront-guided treatment in one eye, and conventional treatment in the other.


Condition Intervention
Myopia Procedure: Laser in situ keratomileusis (LASIK)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Wavefront-guided LASIK for Correction of Myopia

Further study details as provided by Anders Ivarsen, Aarhus University Hospital:

Primary Outcome Measures:
  • Visual acuity [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Ocular higher order aberrations [ Time Frame: 12 months ]
    Hartmann-Schack wavefront aberrometry using the Zeiss Meditec WASCA


Enrollment: 0
Study Start Date: May 2011
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Wavefront-guided LASIK
One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
Procedure: Laser in situ keratomileusis (LASIK)
Wavefront guided treatment in one eye, conventional in the other.
Other Names:
  • Device: Carl Zeiss Meditec Visumax femtosecond LASIK
  • Device: Carl Zeiss Meditec MEL-80 excimer laser.
Active Comparator: Conventional LASIK
One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
Procedure: Laser in situ keratomileusis (LASIK)
Wavefront guided treatment in one eye, conventional in the other.
Other Names:
  • Device: Carl Zeiss Meditec Visumax femtosecond LASIK
  • Device: Carl Zeiss Meditec MEL-80 excimer laser.

  Eligibility

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 20 to 50 years
  • No known ocular or systemic disease
  • Not pregnant or breastfeeding
  • Myopia between -6.0 and -10.0 diopters
  • Astigmatism below 2.0 diopters
  • Difference of less than 1.0 diopters in spherical equivalent between eyes
  • Normal corneal topography
  • Corneal thickness sufficient for planned treatment

Exclusion Criteria:

  • Patients that do not fulfill inclusion criteria
  • Insufficient quality of ocular wavefront measurement
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01682434

Locations
Denmark
Department of Ophthalmology, Aarhus University Hospital
Aarhus, Denmark, DK-8000
Sponsors and Collaborators
Aarhus University Hospital
Investigators
Principal Investigator: Anders Ivarsen, MD, PhD Aarhus University Hospital
  More Information

Responsible Party: Anders Ivarsen, MD, PhD, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT01682434     History of Changes
Other Study ID Numbers: AUH_LASIK
Study First Received: September 4, 2012
Last Updated: April 30, 2014

Additional relevant MeSH terms:
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on August 18, 2017